- Home
- Publications
- Publication Search
- Publication Details
Title
TRAIL receptor signaling and therapeutics
Authors
Keywords
-
Journal
EXPERT OPINION ON THERAPEUTIC TARGETS
Volume 14, Issue 10, Pages 1091-1108
Publisher
Informa Healthcare
Online
2010-09-07
DOI
10.1517/14728222.2010.519701
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer
- (2010) T Trarbach et al. BRITISH JOURNAL OF CANCER
- TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death
- (2010) Kageaki Kuribayashi et al. CANCER BIOLOGY & THERAPY
- LBY135, a novel anti-DR5 agonistic antibody induces tumor cell-specific cytotoxic activity in human colon tumor cell lines and xenografts
- (2010) Jing Li et al. DRUG DEVELOPMENT RESEARCH
- Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors
- (2009) H. A. Wakelee et al. ANNALS OF ONCOLOGY
- miR-221&222 Regulate TRAIL Resistance and Enhance Tumorigenicity through PTEN and TIMP3 Downregulation
- (2009) Michela Garofalo et al. CANCER CELL
- Cullin3-Based Polyubiquitination and p62-Dependent Aggregation of Caspase-8 Mediate Extrinsic Apoptosis Signaling
- (2009) Zhaoyu Jin et al. CELL
- Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study
- (2009) C. H. Mom et al. CLINICAL CANCER RESEARCH
- Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic Study
- (2009) Stephen Leong et al. JOURNAL OF CLINICAL ONCOLOGY
- PU.1 induces apoptosis in myeloma cells through direct transactivation of TRAIL
- (2009) S Ueno et al. ONCOGENE
- Sp1-Mediated TRAIL Induction in Chemosensitization
- (2008) J. Xu et al. CANCER RESEARCH
- DR5 Receptor Mediates Anoikis in Human Colorectal Carcinoma Cell Lines
- (2008) L. M. Laguinge et al. CANCER RESEARCH
- Death receptors as targets for anti-cancer therapy
- (2008) Kerstin Papenfuss et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development
- (2008) Anne Grosse-Wilde et al. JOURNAL OF CLINICAL INVESTIGATION
- TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis
- (2008) Niklas Finnberg et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer
- (2008) F. Anthony Greco et al. LUNG CANCER
- The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway
- (2008) S Wang ONCOGENE
- MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer
- (2008) M Garofalo et al. ONCOGENE
- Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease
- (2008) K. Takeda et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now